No article text was recorded for this version.
acquired therapeutic resistance (multi-target kinase inhibition)
Version 1 of 162 papers80 conceptsfrozen 2026-10-04
Papers in this version
- Blog: Design, Synthesis and Biological Evaluation of Multi-Target Anti-Cancer Agent PYR26
- Blog: Therapeutic potential of tyrosine-protein kinase MET in osteosarcoma
- Blog: Narazaciclib, a novel multi-kinase inhibitor with potent activity against CSF1R, FLT3 and CDK6, shows strong anti-AML activity in defined preclinical models
- Blog: Flavonoids with Anti-Angiogenesis Function in Cancer
- Blog: Remodeling tumor microenvironment with natural products to overcome drug resistance
- Blog: Model-based analysis of response and resistance factors of cetuximab treatment in gastric cancer cell lines
- Blog: Progestin Resistance and Corresponding Management of Abnormal Endometrial Hyperplasia and Endometrial Carcinoma
- Blog: Gastric cancer treatment: recent progress and future perspectives
- Blog: The dual effect of endoplasmic reticulum stress in digestive system tumors and intervention of Chinese botanical drug extracts: a review
- Blog: Continuing Cetuximab <i>vs</i> Bevacizumab plus chemotherapy after first progression in wild-type <i>KRAS</i>, <i>NRAS</i> and <i>BRAF V600E</i> metastatic colorectal cancer: a randomized phase II trial
- Blog: Recent Trends in anti-tumor mechanisms and molecular targets of celastrol
- Blog: Broussonetia kazinoki modulates the expression of VEGFR-2 and MMP-2 through the inhibition of ERK, Akt and p70S6K-dependent signaling pathways: Its implication in endothelial cell proliferation, migration and tubular formation
- Blog: Glasdegib in combination with temozolomide and radiotherapy in adult patients with newly diagnosed glioblastoma: the phase Ib/II GEINO 1602 trial
- Blog: Mammary Development and Breast Cancer: a Notch Perspective
- Blog: Targeting the Sheddase Activity of ADAM17 by an Anti-ADAM17 Antibody D1(A12) Inhibits Head and Neck Squamous Cell Carcinoma Cell Proliferation and Motility via Blockage of Bradykinin Induced HERs Transactivation
- Blog: Mechanism of Bazhen decoction in the treatment of colorectal cancer based on network pharmacology, molecular docking, and experimental validation
- Blog: Network-based Computational Drug Combination Prediction
- Blog: Sensitization effect of kaempferol from persimmon leaves on HepG2 hepatoma cells with ABT-199 resistance and its molecular mechanisms
- Blog: Chem2Bio2RDF: a semantic framework for linking and data mining chemogenomic and systems chemical biology data
- Blog: Targeting Mutant Kirsten Rat Sarcoma Viral Oncogene Homolog in Non-Small Cell Lung Cancer: Current Difficulties, Integrative Treatments and Future Perspectives
- Blog: Safety and Efficacy of Multiple Escalating Doses of RC28-E for Neovascular Age-Related Macular Degeneration: A Phase 1b Trial
- Blog: Induction of N-Ras degradation by flunarizine-mediated autophagy
- Blog: Case Report: Clinical benefit from multi-target tyrosine kinase inhibitor and PARP inhibitor in a patient with cancer of unknown primary with BRCA1 large genomic rearrangement
- Blog: Alteration in Mir-21/PTEN Expression Modulates Gefitinib Resistance in Non-Small Cell Lung Cancer
- Blog: The tumor microenvironment of non–small cell lung cancer impairs immune cell function in people with HIV
- Blog: Erianin induces apoptosis and pyroptosis via MAPK/ERK and PI3K/Akt pathways and synergizes with anlotinib in anaplastic thyroid carcinoma
- Blog: Phase I dose escalation study and pilot efficacy analysis of LXI-15029, a novel mTOR dual inhibitor, in Chinese subjects with advanced malignant solid tumors
- Blog: Advances in the intrinsic signaling pathway interactions and clinical translation of HR+/HER2+ breast cancer
- Blog: The enhanced antitumor activity of bispecific antibody targeting PD-1/PD-L1 signaling
- Blog: Synthetic progress and anti-leukemic research on indirubin analogues: a review since 2010
- Blog: Safety and Efficacy of Hypofractionated Stereotactic Radiotherapy with Anlotinib Targeted Therapy for Glioblastoma at the First Recurrence: A Preliminary Report
- Blog: Roles of estrogen receptor α in endometrial carcinoma (Review)
- Blog: A combinatorial screening protocol for identifying novel and highly potent dual-target inhibitor of BRD4 and STAT3 for kidney cancer therapy
- Blog: Predicting therapeutic drugs for hepatocellular carcinoma based on tissue-specific pathways
- Blog: Using Structure-guided Fragment-Based Drug Discovery to Target Pseudomonas aeruginosa Infections in Cystic Fibrosis
- Blog: Yi Ai Fang, a traditional Chinese herbal formula, impacts the vasculogenic mimicry formation of human colorectal cancer through HIF-1α and epithelial mesenchymal transition
- Blog: Diffusion mapping of drug targets on disease signaling network elements reveals drug combination strategies
- Blog: <sup>18</sup>F-FDG PET as an imaging biomarker for the response to FGFR-targeted therapy of cancer cells via FGFR-initiated mTOR/HK2 axis
- Blog: Ranibizumab non-response in pachychoroid neovasculopathy: Effects of switching to aflibercept
- Blog: DET induces apoptosis and suppresses tumor invasion in glioma cells via PI3K/AKT pathway
- Blog: Present Advances and Future Perspectives of Molecular Targeted Therapy for Osteosarcoma
- Blog: Biological role and expression of translationally controlled tumor protein (TCTP) in tumorigenesis and development and its potential for targeted tumor therapy
- Blog: Contribution of EGFR and ErbB-3 Heterodimerization to the EGFR Mutation-Induced Gefitinib- and Erlotinib-Resistance in Non-Small-Cell Lung Carcinoma Treatments
- Blog: Antifungal Activity and Multi-Target Mechanism of Action of Methylaervine on Candida albicans
- Blog: Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity,
- Blog: Genotype-determined EGFR-RTK heterodimerization and its effects on drug resistance in lung Cancer treatment revealed by molecular dynamics simulations
- Blog: Case report: Successful treatment of refractory membranous nephropathy with telitacicept
- Blog: Safety and Efficacy of Hypofractionated Stereotactic Radiotherapy with Anlotinib Targeted Therapy for Glioblastoma at First Recurrence: A Preliminary Report
- Blog: UNBS5162 induces growth inhibition and apoptosis via inhibiting PI3K/AKT/mTOR pathway in triple negative breast cancer MDA‑MB‑231 cells
- Blog: Stimulator of interferon response cGAMP interactor overcomes ERBB2-mediated apatinib resistance in head and neck squamous cell carcinoma
- Blog: Community assessment to advance computational prediction of cancer drug combinations in a pharmacogenomic screen
- Blog: Coexpression of the IGF-IR, EGFR and HER-2 is common in colorectal cancer patients
- Blog: The FOXM1–ABCC5 axis contributes to paclitaxel resistance in nasopharyngeal carcinoma cells
- Blog: Pharmacological targeting of caspase-8/c-FLIPL heterodimer enhances complex II assembly and elimination of pancreatic cancer cells
- Blog: Triple-Negative Breast Cancer Cells Recruit Neutrophils by Secreting TGF-β and CXCR2 Ligands
- Blog: Design, Synthesis and Biological Activity Testing of Library of Sphk1 Inhibitors
- Blog: FGFR gene amplification and response to HER2-targeted therapy in patients with HER2-expressing metastatic breast cancer
- Blog: Retinal and choroidal efficacy of switching treatment to faricimab in recalcitrant neovascular age related macular degeneration
- Blog: Distinct DNA Methylation Patterns of Subependymal Giant Cell Astrocytomas in Tuberous Sclerosis Complex
- Blog: The Synergistic Effects of Pyrotinib Combined With Adriamycin on HER2-Positive Breast Cancer
Showing 60 of 62 papers.
History & citation
Current · Permanent link
- This direction split from Neutralizing Compensatory Signaling and Biological Redundancy (50% overlap)
Cite this direction
Latest version (a living page):
@misc{lacuna_acquired_therapeutic_resistance_multi_ta_ad4a19b8,
title = {acquired therapeutic resistance (multi-target kinase inhibition)},
author = {{Lacuna}},
howpublished = {Lacuna research direction},
year = {2026},
url = {https://lacuna.tiptreesystems.com/direction/acquired-therapeutic-resistance-multi-target-kinase-inhibition/rdr_ad4a19b8669244a6877c4d958504a6de},
note = {Latest version of a living research direction; cite a version for a fixed text. Accessed 2026-11-22},
}This exact version (version 1, frozen text):
@misc{lacuna_acquired_therapeutic_resistance_multi_ta_ad4a19b8_v1,
title = {acquired therapeutic resistance (multi-target kinase inhibition)},
author = {{Lacuna}},
howpublished = {Lacuna research direction},
year = {2026},
url = {https://lacuna.tiptreesystems.com/direction/acquired-therapeutic-resistance-multi-target-kinase-inhibition/rdr_ad4a19b8669244a6877c4d958504a6de/v/1},
note = {Version 1, frozen 2026-10-04. Accessed 2026-11-22},
}